ACUTE PULMONARY EMBOLISMS
Diagnosis and Management
Kartika Widayati Tarono-Harjadi
* Hematology and Medical Oncology, Department of Internal Medicine, Dr. Sardjito General Hospital/Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia

ABSTRACT
Acute pulmonary embolisms is a major cause of complications and death associated in surgery, medical illnesses, injury, and also may occurs after a long-distance air travel. It is often originating from deep-vein thrombosis and has a wide spectrum of clinical manifestation ranging from asymptomatic, incidentally discovered emboli, to massive embolism causing immediate death. Incidence of pulmonary embolism ranges from 23-69 cases per 100,000 populations. Case fatality rates vary widely depending on the severity of the cases; at an average case fatality rate within 2 week of diagnosis of approximately 11%. It may have chronic sequlae as post thrombotic syndrome and chronic thromboembolism pulmonary hypertension. Acute pulmonary embolism is often difficult to diagnose. The predisposing factors for pulmonary embolisms consist of hereditary factors, acquired factors, and probable factors. Patients with symptoms of dyspnea, chest apnea, tachypnea or tachycardia arise suspicion of pulmonary embolisms therefore should be screened their probability for developing the disease. Low risk patients will then be evaluated for d-dimer test. Treatment should be initiated promptly in high risk patients, followed by imaging procedure evaluation. Chest radiographs, CT scan arteriography, VQ scan are performed to either include or exclude diagnosis of pulmonary embolisms.

Pathophysiology
Thrombi arises from deep veins in the lower extremity, propagate in the proximal veins include popliteal veins and their upper veins, in which is easier to form embolization. Emboli migrates from right ventricle and plugs pulmonary arterial.
In acute PE, anatomical obstruction will decrease pulmonary function, followed by secretion of vasoactive and bronchoactive mediators that lead
to impairment of ventilation-perfusion. Increasing of right ventricle wall pressure cause ventricle dilatation, dysfunction, and ischemic of right ventricle. Death may caused by right ventricular failure.

Risk Factors

Many health's condition and genetic factors increase the risk of PE. All risk factors of DVT become risk factors of PE. Table 1 gives summary of the risk factors of PE including hereditary and acquired risk factors.

Table 1. Risk Factors of Venous Thromboembolisms (Deep Vein Thrombosis and Pulmonary Embolisms)

<table>
<thead>
<tr>
<th>Acquired</th>
<th>Genetic</th>
<th>Possible</th>
</tr>
</thead>
<tbody>
<tr>
<td>immobilation</td>
<td>platelet anticoagulant</td>
<td>Increase of fibrinogen (a)</td>
</tr>
<tr>
<td>elderly</td>
<td>Protein C deficiency</td>
<td>Lack of Tissue factor inhibitor pathway</td>
</tr>
<tr>
<td>cancer</td>
<td>Oral contraceptive</td>
<td>Hyperhomocysteine</td>
</tr>
<tr>
<td>Acute illness</td>
<td>Factor V Leiden mutation</td>
<td>Increase factor VIII</td>
</tr>
<tr>
<td>trauma</td>
<td>Resistant to active protein</td>
<td>Increase of factor IX</td>
</tr>
<tr>
<td>Major surgery</td>
<td>chemotherapy</td>
<td>Increase of factor IX</td>
</tr>
<tr>
<td>Spinal injury</td>
<td>Obesity</td>
<td>Increase of fibrinogen inhibitor</td>
</tr>
<tr>
<td>pregnancy</td>
<td>Centr vein catheter</td>
<td></td>
</tr>
<tr>
<td>PDA</td>
<td>cast and immobilizer</td>
<td></td>
</tr>
</tbody>
</table>

Diagnosis approach

Symptoms of PE are not specific. Dyspnea, tachycardia, pleuritic pain, and hemoptysis are sometimes found in patients with PE as well as other diseases. Cough, palpitation, light headedness, fever, and rales are common symptoms and signs which may be obscured by presenting comorbid illness. Symptoms and signs of pulmonary hypertension like elevation of jugular vein pressure, loud P2, gallops on the right ventricle, and elevation of right heart configuration may raise suspicion to PE but neither sensitive nor specific. Electrocardiography showed unexplained sinus tachycardia, and SIQT3 pattern in massive pulmonary embolisms, right bundle branch block, P pulmonale, and right axis deviation.

Patient with PE usually present with hypoxemia, but somehow blood gas analysis showed normal results in large number of patients. Cyanosis, hypotension, and syncope may preceded a fatal and massive PE that lead to death. Troponin may increase in PE but should not be used as diagnosis marker; its indication is recommended for prognostic stratification.

Upon suspicion of PE, physician should perform a comprehensive and detailed anamnesis, assessment of prediction probability of PE and its risk factors, biomarker test and diagnostic imaging.

A simple method to predict thromboembolism is developed by Wells et al using Clinical Prediction Rules for Pulmonary Embolism. Beside Wells criteria, it has been developed other prediction criteria using more complicated items, radiographic imaging, and electrocardiography that should be interpreted by an expert.

Table 2. Wells Clinical Prediction Rule for Pulmonary Embolism (PE)

<table>
<thead>
<tr>
<th>Clinical feature</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical symptoms of DVT</td>
<td>3</td>
</tr>
<tr>
<td>Other diagnosis less likely than PE</td>
<td>3</td>
</tr>
<tr>
<td>Heart rate greater than 100 beats per minute</td>
<td>1.5</td>
</tr>
<tr>
<td>Immobilization or surgery within past 4 weeks</td>
<td>1.5</td>
</tr>
<tr>
<td>Previous DVT or PE</td>
<td>1.5</td>
</tr>
<tr>
<td>Malignancy</td>
<td>1</td>
</tr>
<tr>
<td>Total points</td>
<td>12.5</td>
</tr>
</tbody>
</table>

Risk score interpretation (probability of PE):

- >6 points: high risk (78.4%);
- 2 to 6 points: moderate risk (27.8%);
- <2 points: low risk (3.4%).

Diagnostic Imaging

Patients with low probability of PE at outpatient setting should undergo D-Dimer test. D-dimer is a method to measure degradation product of cross linked-fibrin in the blood circulation. This method has a high sensitivity value but low specificity. Increasing of D-dimer is almost always happened in patients with emboli, as well as in elderly, trauma, post surgery, pregnancy, inflammation, and cancer. In patients with low risk probability and high D-Dimer results using highly sensitive D-Dimer assay should be followed by imaging diagnostic procedures. In publication by Gibson et al D-Dimer test should be performed after clinical probability assessment or clinical prediction rule has done. High clinical probability patients should undergo other testing, regardless the D-Dimer outcome.

Treatment should be initiated promptly for high risk probability patients, while concomitantly carrying out diagnostic procedures such as helical CT scanning, ventilation-perfusion scanning, pulmonary arteriography until diagnosis is established. Ventilation-perfusion scanning has the important role in diagnosing PE for almost 3 decades. Positive results from ventilation-perfusion scanning (V/Q scanning) gives high sensitivity for thromboembolism. However many large trial showed patients with emboli showed normal ventilation-perfusion scanning. Computed Tomography scanning has superiority compared with ventilation-perfusion scanning in term of either sensitivity or specificity. Helical CT scan has 57-100% sensitivity and 78-100% specificity. If the helical CT showed negative for PE, the likelihood of PE diagnosis is low, but can not directly exclude PE diagnosis as well as ventilation perfusion scanning. A negative result of multidetector-row CT can safely rule out PE diagnosis.
Evaluation of veins in lower extremities should always be performed as PE arise from DVT. Duplex USG will be positive in 10-20% patients without symptoms in their leg, and USG of lower extremities' veins will positive in 50% patients with emboli. Normal USG duplex does not exclude diagnosis of emboli.

Gold standard in PE diagnosis is pulmonary angiography. This invasive procedure needs specialist technique and expert interpreter. Pulmonary angiography should be performed in condition where other non invasive diagnostic procedures are not conclusive.

Treatment
Upon established diagnosis, patient with PE should be hospitalized and resting for the first 48 hours. If there were no contraindications, anticoagulation with heparin or low molecular weight heparin should be continued for up to 6 month. Unprovoked VTE is continued for up to 6 month. Unprovoked VTE is also associated with right ventricular dysfunction at hospital discharge from first episode of PE is also associated with right ventricular dysfunction. Nomogram for predicting recurrency in unprovoked VTE has been developed by scoring sex, location of VTE, and d-Dimer results.

SUMMARY
Physicians should aware of pulmonary embolism. Diagnosing PE is not always easy. Patients with unexplained dyspnea, tachycardia, hemoptosis, with or without deep vein thrombosis should be assessed probability of PE with clinical probability test developed by Wells. Those with high and moderate probability should be initiated treatment while waiting further test. Higher d-dimer value directs to chest x ray and multidetector chest CT. If PE was detected by imaging, anticoagulation therapy is contraindicated, mechanical pulmonary embolectomy should be performed.

### Table 3. Initial treatment for PE management

<table>
<thead>
<tr>
<th>Drug</th>
<th>Mode of Administration</th>
<th>Note</th>
<th>Drug</th>
<th>Mode of Administration</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>unfractionated heparin (intravenous infusion)</td>
<td>80U/kg BW bolus iv continued with 18 IU/kg BW hours continuous infusion</td>
<td>Adjust the rate to achieve aPTT 1.5-2.5 times control monitor thrombocyte every 2 days starting from day -4 up to da-14 or until heparin is stopped. Aware of HIT if thrombocyte count decrease more than 50% OR developed thrombosis.</td>
<td>Low molecular weight heparin (LMWH)</td>
<td>LMWH is not recommended for PE with hypertension or shock</td>
<td></td>
</tr>
<tr>
<td>enoxaparin</td>
<td>1.0 mg/kg BW every 12 hours sc or 1.5 mg/kg BW once daily</td>
<td>If creatinin clearance &lt;30 ml/minute reduce dose to 1 mg/kg BW/day or substitute with UFH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>fondaparinux</td>
<td>5 mg for body weight &lt; 50 kg and 7.5 mg for body weight 50-100 kg and 10 mg for body weight &gt; 100 kg</td>
<td>Contraindicated for creatinin clearance &lt; 30 ml</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### REFERENCES


25. Becattini C., Agnelli G., Pesante R. Incidence of Chronic Thromboembolic Pulmonary Hypertension after a First Episode of Pulmonary Embolism. *Chest* 2006;130:172–175

